Aureus Asset Management LLC Purchases 542 Shares of Eli Lilly and Company $LLY

Aureus Asset Management LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 15.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,008 shares of the company’s stock after acquiring an additional 542 shares during the quarter. Aureus Asset Management LLC’s holdings in Eli Lilly and Company were worth $3,686,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Spire Wealth Management increased its stake in shares of Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Eli Lilly and Company by 30.8% during the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares in the last quarter. Iams Wealth Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $754,000. May Hill Capital LLC boosted its holdings in Eli Lilly and Company by 131.6% in the 4th quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock worth $3,408,000 after buying an additional 1,801 shares during the period. Finally, Caisse Des Depots ET Consignations boosted its holdings in Eli Lilly and Company by 17.3% in the 4th quarter. Caisse Des Depots ET Consignations now owns 10,834 shares of the company’s stock worth $11,643,000 after buying an additional 1,600 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 1.0%

LLY opened at $1,163.70 on Thursday. The company has a market capitalization of $1.10 trillion, a PE ratio of 41.34, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The firm has a 50-day simple moving average of $1,129.17 and a two-hundred day simple moving average of $1,038.31. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 34.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Wall Street Analyst Weigh In

A number of research firms have commented on LLY. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research note on Monday, July 6th. Royal Bank Of Canada increased their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. Sanford C. Bernstein lifted their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Finally, JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Neutral Sentiment: Eli Lilly confirmed it will report second-quarter 2026 results on August 5, with a conference call the same day, keeping attention on the company’s upcoming earnings update. Lilly confirms date and conference call for second-quarter 2026 financial results announcement
• Neutral Sentiment: An update on Lilly’s EMPRISE diabetes study added some interest in the company’s clinical data pipeline, but the market’s focus is still centered on the legal battle with Novo Nordisk. Real-World Diabetes Data: What Eli Lilly’s EMPRISE Update Means for LLY Investors
• Positive Sentiment: Broader pharma stocks got a lift after reports that generic drugs imported into the U.S. will remain under a zero-percent tariff for two more years, which could support sentiment across the sector, including Lilly. These major drug stocks rally after Trump’s zero tariff announcement

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.